吉西他滨联合顺铂治疗头颈部癌52例分析

目的 评价吉西他滨联合顺铂治疗复发转移性头颈部癌患者的疗效和毒性。方法 52例复发转移性头颈部癌患者接受吉西他滨联合顺铂方案：吉西他滨1000mg／m^2,第1天和第8天;顺铂25mg／m^2,第1～3天;21d为1个疗程。结果 可评价患者52例,3例（5．8％）达完全缓解,19例（36．5％）达部分缓解,有效率42．3％（22／52）。中位疾病进展时间5．0个月,中位生存期9．9个月,1年生存率为43．4％。在既往经含铂方案化疗的32例患者中,2例（6．3％）达完全缓解,11例（34．4％）达部分缓解,有效率为40．6％（13／32）。中位疾病进展时间3．4个月,中位生存期8．3个月,1年生存率为29．2％。主要不良反应为1或2度血液学毒性、皮疹和恶心呕吐。结论 吉西他滨联合顺铂是治疗晚期复发转移性头颈部癌患者安全、有效的联合化疗方案．

Experience of gemcitabine plus cisplatin chemotherapy in 52 patients with head and neck cancer

Objective To evaluate the efficacy and toxicity of combination chemotherapy using gemcitabine plus cisplatin for recurrent and/or metastastic head and neck cancer patients. Methods Fifty-two patients with recurrent or metastatic head and neck cancer were treated by gemcitabine 1000 mg/m2 on D1, 8 and cisplatin 25 mg/m2 on D1~3 every 21 days as one cycle. Results Of 52 assessable patients, 3(5.8%) showed complete response and 19 (36.5%) partial response with an overall response rate of 42.3% (22/52). Median time to progression was 5.0 months,and 1-year survival was 43.4% with a median survival time of 9.9 months. Of 32 previously treated patients by cisplatin-containing regimen, 2 patients (6.3%) gave complete response and 11 (34.4%) partial response with an overall response rate of 40.6%(13/32). Median time to progression was 3.4 months,and 1-year survival was 29.2% with a median survival time of 8.3 months. Toxicity mainly included grade 1/2 myleosuppression, rash and nausea/vomiting. Conclusion Gemcitabine plus cisplatin chemotherapy is safe and effective for patients with recurrent and/or metastastic head and neck cancer.